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Abstract
Background: In response to viral infection, the innate immune system recognizes viral nucleic acids and then induces
production of proinflammatory cytokines and type I interferons (IFNs). Toll-like receptor 7 (TLR7) and TLR9 detect viral RNA
and DNA, respectively, in endosomal compartments, leading to the activation of nuclear factor kB (NF-kB) and IFN
regulatory factors (IRFs) in plasmacytoid dendritic cells. During such TLR signaling, TNF receptor-associated factor 6 (TRAF6)
is essential for the activation of NF-kB and the production of type I IFN. In contrast, RIG-like helicases (RLHs), cytosolic RNA
sensors, are indispensable for antiviral responses in conventional dendritic cells, macrophages, and fibroblasts. However, the
contribution of TRAF6 to the detection of cytosolic viral nucleic acids has been controversial, and the involvement of TRAF6
in IRF activation has not been adequately addressed.
Principal Findings: Here we first show that TRAF6 plays a critical role in RLH signaling. The absence of TRAF6 resulted in
enhanced viral replication and a significant reduction in the production of IL-6 and type I IFNs after infection with RNA virus.
Activation of NF-kB and IRF7, but not that of IRF3, was significantly impaired during RLH signaling in the absence of TRAF6.
TGFb-activated kinase 1 (TAK1) and MEKK3, whose activation by TRAF6 during TLR signaling is involved in NF-kB activation,
were not essential for RLH-mediated NF-kB activation. We also demonstrate that TRAF6-deficiency impaired cytosolic DNA-
induced antiviral responses, and this impairment was due to defective activation of NF-kB and IRF7.
Conclusions/Significance: Thus, TRAF6 mediates antiviral responses triggered by cytosolic viral DNA and RNA in a way that
differs from that associated with TLR signaling. Given its essential role in signaling by various receptors involved in the
acquired immune system, TRAF6 represents a key molecule in innate and antigen-specific immune responses against viral
infection.
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Introduction
Innate immune responses to viruses are triggered when the host
recognizes specific viral nucleic acid and surface glycoprotein
structures, called pathogen-associated molecular patterns (PAMPs)
[1–3]. After viral infection, pattern-recognition receptors (PRRs),
such as Toll-like receptors (TLRs), RIG-I-like helicases (RLHs), and
cytosolic DNA sensor proteins, recognize viral PAMPs and then
activate various transcription factors, including nuclear factor-kB
(NF-kB) and interferon (IFN) regulatory factors (IRFs), to induce the
production of proinflammatory cytokines and type I IFNs (IFNa and
IFNb), respectively. Several lines of evidence indicate that PRRs
recognize viral nucleic acids in a cell-type-specific manner [4,5].
TLR7 and TLR9 are responsible for detection of viral RNA and
DNA, respectively, in the endosomal compartments of plasmacytoid
dendriticcells(pDCs),whereasRLHsdetectviralRNAinthecytosol
of conventional DCs (cDCs), macrophages, and fibroblasts.
During TLR7 and TLR9 signaling, TLRs bind to their ligand
and then interact with the adaptor protein called myeloid
differentiation primary response gene 88 (MyD88) [6]. MyD88
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(IRAK) family such as IRAK1 and IRAK4, which activate TNF
receptor-associated factor 6 (TRAF6). TRAF6 is an E3 ubiquitin
ligase that catalyzes the formation of Lys-63-linked polyubiquiti-
nation on TRAF6 itself and IkB kinase c (IKKc also known as
NEMO) [7,8]. Subsequently, a complex of TAK1, TAK1 binding
protein 2 (TAB2), and TAB3 is recruited to TRAF6 [9,10]. TAK1
activates the IKK complex, leading to NF-kB activation and
induction of proinflammatory cytokine expression, which is also
enhanced by TRAF6- and MyD88-activated IRF5 [11]. In
addition, upon viral infection, TRAF6 forms a complex with
IRF7 together with MyD88 [12,13], IRAK4 [13], and IRAK1
[14]. IRF7 is then phosphorylated by IRAK1 and/or IKKa [15],
which result in dimer formation and nuclear translocation of
IRF7, leading to the production of type I IFNs. Thus, TRAF6
plays a pivotal role in TLR7 and TLR9 signaling.
RLHs, such as RIG-I and the protein product of the melanoma
differentiation-associated gene 5 (MDA5), contain two functional
domains: an RNA helicase domain and a caspase recruitment
domain (CARD) [16,17]. The RNA helicase domain recognizes
viral RNA, synthetic double-stranded RNA (dsRNA), and 59-
triphosphate RNA [18,19], and the CARD domain interacts with
the CARD-like domain of the IFNb promoter stimulator-1 (IPS-1,
also known as MAVS/VISA/Cardif) [20–23]. Upon viral
infection, IPS-1 associates with RIG-I or MDA5 at the
mitochondrial outer membrane via the CARD-CARD interaction,
which is essential for triggering downstream signaling that
activates NF-kB and IRF. RLH signaling has been proposed to
bifurcate at IPS-1 into the TRAF3-dependent IRF activation
pathway and the TRAF6-dependent NF-kB activation pathway
[3]. The TRAF3-dependent pathway has been genetically
confirmed by experiments showing that Traf3
2/2 MEF cells show
impaired production of type I IFNs but normal activation of NF-
kB in response to viral infection [24,25]. Furthermore, TRAF3
associates with TANK-binding kinase 1 (TBK1) and inducible
IKK (IKKi, also known as IKKe) [24], which phosphorylate and
activate IRF3 and IRF7 [26,27]. In contrast, the function of
TRAF6 in innate immune responses to cytosolic viral RNA has
been controversial [21,22,28–30], although mutation of TRAF6-
binding sites in IPS-1 resulted in a marked reduction of IPS-1-
induced NF-kB activation in a transient transfection assay [22].
Furthermore, the role of TRAF6 in IRF activation during RLH
signaling has never been adequately addressed.
In addition to RLH signaling, recent studies have reported
that cytosolic DNA sensors initiate TLR9-independent innate
immune responses [31–34]. Intracellular administration of viral
DNA or synthetic double-stranded B-form DNA (B-DNA)
triggers antiviral responses, including the production of proin-
flammatory cytokines and type I IFNs. IRF3 is activated by
TBK1 and IKKi in response to B-DNA transfection [32],
suggesting that cytosolic DNA activates signaling pathways
similar to RLH signaling. Interestingly, while RLH signaling
totally depends on IPS-1, contribution of IPS-1 to the cytosolic
DNA sensing signaling has been controversial; one group
reported dispensability of IPS-1 whereas the other reported
partial involvement of IPS-1 in the cytosolic DNA sensing
signaling [35,36]. This suggests that cytosolic DNA and RNA are
detected by different pathways. Therefore, the precise signaling
mechanisms associated with DNA sensing, including the role of
TRAF6, remain to be elucidated.
In this study, we demonstrate that TRAF6 functions as a critical
signal transducer for sensing both cytosolic RNA and DNA and
thereby helps to trigger antiviral responses in a way that differs
from that associated with TLR7 and TLR9 signalings.
Results
TRAF6 is involved in the RLH-mediated
signaling pathway
To address whether TRAF6 is involved in RLH-induced innate
immune responses, we first assessed whether TRAF6 induces
production of IL-6 and type I IFN in response to RNA virus
infection. Sendai virus (SeV), a negative sense single-stranded
RNA (ssRNA) virus, is recognized by RIG-I [4]. The SeV Cm
mutant, which carries a mutated C protein, and the V-mutant,
which lacks the V protein, were used because these viral accessory
proteins suppress IFN responses [37,38]. When infected with
mutant SeV strains, Traf6
2/2 MEF cells showed no detectable
induction of IL-6 production compared with the substantial
induction in Traf6
+/+ MEF cells (Figure 1A, top). Secretion of type
I IFNs after SeV infection was significantly lower in the absence of
TRAF6 (Figure 1A, middle and bottom). Furthermore, TRAF6
deficiency resulted in impaired activation of the IFNb promoter in
response to infection with encephalomyocarditis virus (EMCV), a
positive-sense ssRNA virus recognized by MDA5 (Figure 1B)
[39,40]. To further characterize the roles of TRAF6 in RLH
signaling, synthetic double-stranded RNAs (dsRNAs) were tested.
Poly I:C and in vitro transcribed dsRNA were detected by MDA5
and RIG-I, respectively [39]. IL-6 and IFNa production were
significantly lower in response to transfection with poly I:C and in
vitro-transcribed dsRNA using Lipofectamine (Figure 1C). Fur-
thermore, the amount of viral C protein after SeV Cm infection of
Traf6
2/2 MEF cells was higher than that in Traf6
+/+ MEF cells at
all time points tested after virus infection (Figure S1). Taken
together, these results indicate that TRAF6 is crucial for both
RIG-I- and MDA5-mediated antiviral responses.
TRAF6 contributes to efficient elimination of RNA viruses
Because TRAF6 is required for efficient production of type
IFNs during antiviral responses, we next analyzed the contribution
of TRAF6 to eliminating RNA viruses. Quantification of viral
replication by the plaque assay showed that viral yields were
significantly higher in Traf6
2/2 MEF cells than in Traf6
+/+ MEF
cells at 48 and 72 h after infection with Newcastle disease virus
(NDV), a negative-sense ssRNA recognized by RIG-I [39]
(Figure 2A). The amount of IFNa secreted in response to NDV
infection was significantly reduced in the absence of TRAF6
(Figure 2B). In addition, replication of EMCV was also
significantly enhanced in the absence of TRAF6 (Figure 2C).
Thus, TRAF6 contributes to effective elimination of RNA viruses
that activate MDA5 pathway as well as those activate RIG-I
pathway through production of sufficient amount of type I IFN.
During RLH signaling, TRAF6 plays a critical role in
activating NF-kB and IRF7, but not in activating IRF3
Induction of proinflammatory cytokines and type I IFNs is
essential for initial antiviral responses, which lead to the activation
of adaptive immunity. Activation of transcription factors including
NF-kB, IRF3, and IRF7 is a prerequisite for the efficient secretion
of these cytokines. Therefore, we first checked whether TRAF6 is
involved in activating NF-kB during RLH signaling. Activation of
the NF-kB-driven luciferase promoter (NF-kB-luc) induced by
intracellular administration of poly I:C was impaired in Traf6
2/2
MEF cells (Figure 3A). Induction of the nuclear DNA binding
activity of NF-kB was abrogated in Traf6
2/2 MEF cells in
response to infection with SeV Cm or NDV (Figure 3B and 3C).
Furthermore, expression of IkBa, an NF-kB target gene induced by
NDV infection was significantly reduced in the absence of TRAF6
(Figure 3D), These results indicate that TRAF6 is essential in the
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whether the ubiquitin ligase activity of TRAF6 is required for NF-
kB activation in response to RNA virus infection, we generated a
ligase-deficient mutant of TRAF6 called T6Rm, in which both
Cys-85 and His-87 within the RING domain were substituted with
Ala [7]. Infection with NDV did not induce NF-kB activation in
Traf6
2/2 MEF cells that ectopically expressed T6Rm (Figure 3C),
suggesting that the E3 ubiquitin ligase activity of TRAF6 is
required for NF-kB activation, as is the case in TLR signaling.
Activation of c-Jun N-terminal kinase (JNK) in response to NDV
infection was barely affected (Figure 3E). Interestingly, inactivation
of RING finger of TRAF6 did not affect NDV-induced
production of IFNa (Figure 3F) suggesting that Lys-63-linked
polyubiquitination may not be involved in type I IFN production.
Given that TRAF6 RING finger is required for NF-kB activation,
this observation is consistent with previous reports showing that
lack of p50, Rel, RelA or IKKb barely affected type I IFN
production in response to viral infection [41,42]. Therefore,
TRAF6-mediated activation of NF-kB may not be essential for
type I IFN production by RLH signaling. In contrast, lack of IRF3
or that of IRF7 resulted in significant reduction or abrogation of
the viral infection-induced type I IFN production, respectively
[43]. It has been reported that IRF5 is involved in production of
IL-6 and type I IFN in macrophages but not in MEF cells [44].
Therefore, we next addressed whether TRAF6-deficiency affects
activation of IRF 3 and IRF7 in MEF cells. Activation of the IFNb
promoter (IFNb-luc) and the promoter containing multiple IFN-
stimulated response elements (ISRE-luc) was impaired in response
to poly I:C transfection in the absence of TRAF6 (Figure 4A),
raising the possibility that TRAF6 is involved in the activation of
Figure 1. TRAF6 is involved in both RIG-I- and MDA5-mediated production of IL-6 and type I IFNs. A Traf6
+/+ or Traf6
2/2 MEF cells were
infected with SeV V- or Cm (MOI=10) for 24 h. The amounts of IL-6 (top), IFNa (middle), and IFNb (bottom) present in the culture media were
measured by ELISA. B Traf6
+/+ or Traf6
2/2 MEF cells were transfected with the IFNb-luc reporter plasmid. At 48 h after transfection, MEF cells were
infected with EMCV (MOI=1) for 20 h. The cells were then harvested and analyzed for promoter activity using the luciferase assay. C Traf6
+/+ or
Traf6
2/2 MEF cells were treated with 10 mg/ml of LPS, 10 mg/ml of poly I:C alone (poly I:C) or transfected with 10 mg/ml of poly I:C (poly I:C+lipo), or
1 mg/ml of in vitro-transcribed dsRNA (in vitro-transcribed dsRNA+lipo) using Lipofectamine 2000. At 12 h after transfection, the amounts of IL-6
(upper) and IFNa (lower) present in the culture media were measured by ELISA. All results shown in Figure 1 indicate the mean6SD of triplicate
determinations and are representative of two independent experiments. ND, not detected. NS, not significant. *=P,0.01.
doi:10.1371/journal.pone.0005674.g001
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dispensable for IRF3 activation because the dimerization of IRF3,
an indicator of IRF3 activation, occurred normally in Traf6
2/2
MEF cells following either transfection with poly I:C or infection
with NDV or SeV Cm (Figure 4B and S2). Although activation of
IRF7 is critical for IFN production [43], IRF7 expression is barely
detected during the initial stage of viral infection. To overcome
this problem, human IRF7 (hIRF7) was ectopically expressed in
Traf6
+/+ and Traf6
2/2 MEF cells, as previously reported [42].
Activation of IRF7 was then determined using the anti-p-hIRF7
antibody, which recognizes phosphorylation of serine residues in
the C-terminal region of hIRF7, an indicator of IRF7 activation
[45]. Because both phosphorylated and unphosphorylated IRF7
became degraded upon stimulation as has been reported
previously [46] (Figure 4C, left), we decided to evaluate levels of
IRF7 activation based on the relative values that are expressed as
the intensity of the band detected by anti-p-hIRF antibody at each
time point divided by the intensity of the band detected by anti-
IRF7 antibody at 0 h after stimulation (Figure 4C, right). This is
because ability of TRAF6 to activate IRF7 should be evaluated
amounts of phosphorylated IRF7 generated at certain period after
stimulation as a consequence of both phosphorylation of IRF7 and
degradation of unphosphorylated and phosphorylated IRF7 on the
condition that amounts of IRF7 expressed at 0 h are almost equal
in Traf6
+/+ and Traf6
2/2 MEF cells. Relative amount of
phosphorylated hIRF7 in Traf6
2/2 MEF cells was significantly
lower than those in Traf6
+/+ MEF cells following transfection with
poly I:C (Figure 4C). Furthermore, heavily phosphorylated hIRF7,
which migrates more slowly in SDS gels [47], was clearly evident
in Traf6
+/+ MEF cells, but not in Traf6
2/2 MEF cells (Figure 4C,
left, second panel from the top). The reduced phosphorylation of
IRF7 was not specific to human IRF7: the phosphorylation of
mouse IRF7 (mIRF7), which is detectable as a more slowly
migrating band on SDS gels, was also reduced when cells lacking
TRAF6 and expressing exogenous mIRF7 were transfected with
poly I:C (Figure 4D). Decay of mIRF7 levels after stimulation may
be due to degradation of mIRF7 as has been reported previously
[46]. Reduced activation of IRF7 in the absence of TRAF6 was
further supported by the observation that expression of non-ifna4,
which is regulated by IRF7 [48], in response to NDV infection was
significantly reduced in the absence of TRAF6 (Figure 4E). These
data indicate that TRAF6 is required for efficient activation of
IRF7, but not of IRF3, in the RLH-mediated signaling pathway.
NDV-induced non-ifna4 mRNA expression in Traf6
2/2 MEF cells
was higher than that in Traf6
2/2 MEF cells at 24 h post-infection.
This may be due to reduction of negative feed back that diminishes
IFNa mRNA expression after viral infection in Traf6
2/2 MEF
cells. However, despite this inversion at 24 h after infection, the
Figure 2. TRAF6 contributes to efficient elimination of NDV and EMCV. A&B Traf6
+/+ MEF cells, Traf6
2/2 MEF cells or those exogenously
expressing TRAF6 were infected with NDV [MOI=0.1 (A upper) or 1 (A lower, B)] for the indicated times. Viral titers in the culture media were
determined using the plaque assay (A). The amounts of IFNa present in the culture media were measured by ELISA (B). C Traf6
+/+ or Traf6
2/2 MEF
cells were infected with EMCV (MOI=0.01) for 24 h. Viral titers in the culture media were determined using the plaque assay. All results shown in
Figure 2 represent the mean6SD of triplicate determinations and are representative of two independent experiments. NS, not significant. *=P,0.01.
**=P,0.05.
doi:10.1371/journal.pone.0005674.g002
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2/2 MEF cells
was significantly higher than that from Traf6
2/2 MEF cells in
response to NDV infection at 24 h post-infection and thereafter
(Figure 2B).
Taken together, in the absence of TRAF6, impaired activation
of NF-kB and significantly reduced activation of IRF7 result in
severely reduced expression of IL-6 and type I IFNs (Figure 1), as
well as enhanced replication NDV and EMCV (Figure 2).
Figure 3. TRAF6 is essential for NF-kB activation in RLH-mediated pathways. A Traf6
+/+ or Traf6
2/2 MEF cells were transiently transfected
with NF-kB-luc reporter plasmid. At 48 h after transfection, the cells were transfected with 10 mg/ml of poly I:C for 6 h. Cell lysates were then
analyzed for promoter activity using the luciferase assay. B Traf6
+/+ or Traf6
2/2 MEF cells were infected with SeV Cm (MOI=10) for the indicated
times. NF-kB binding activity was determined by EMSA. Nuclear extract obtained from wild-type MEF cells treated with TNFa (10 ng/ml) was used as
a positive control. C Traf6
2/2 MEF cells were infected with retroviral vector carrying the puromycin resistance gene and encoding TRAF6, T6Rm, or no
protein. Puromycin-resistant pools of MEF cells were infected with NDV (MOI=5) for the indicated times. EMSAs were performed as described in (B)
(left). TRAF6 and T6Rm expression was analyzed (right). D Traf6
+/+ or Traf6
2/2 MEF cells were infected with NDV (MOI=5) for the indicated times. IkBa
gene expression was assessed by real-time PCR. E Traf6
+/+ or Traf6
2/2 MEF cells were infected with NDV (MOI=5) for the indicated times. Cell lysates
were then analyzed for immunoblotting using anti-p-JNK antibody. F Traf6
+/+ MEF cells, Traf6
2/2 MEF cells, and those exogenously expressing TRAF6
or T6Rm were infected with NDV (MOI=5) for 24 h. The amounts of IFNa present in the culture media were measured by ELISA. Results shown in (A),
(D), and (F) represent the mean6SD of triplicate determinations are representative of two independent experiments. *=P,0.01.
doi:10.1371/journal.pone.0005674.g003
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+/+ or Traf6
2/2
MEF cells were transiently transfected with IFNb-luc (left) or ISRE-luc (right) reporter plasmid. At 48 h after transfection, cells were transfected with
10 mg/ml of poly I:C (poly I:C+lipo) for 6 h. Cell lysates were then analyzed for promoter activity using the luciferase assay. B Traf6
+/+ or Traf6
2/2 MEF
cells were transfected with 10 mg/ml of poly I:C (poly I:C+lipo) (left) or infected with NDV (MOI=5) (right) for the indicated times. Cell lysates were
then prepared, and the dimerization of IRF3 was analyzed by native PAGE. C Traf6
+/+ or Traf6
2/2 MEF cells were infected with retrovirus vectors
encoding human IRF7 (hIRF7) carrying the puromycin resistance gene. Puromycin-resistant pools of MEF cells were treated with 10 mg/ml of poly I:C
together with Lipofectamine 2000 (poly I:C+lipo) for the indicated times. Cell lysates were then prepared, and immunoblotting was performed using
antibodies specific to phospho-hIRF7 (p-hIRF7), IRF7, TRAF6, and Tubulin. An open arrowhead denotes unphosphorylated forms and a closed
arrowhead denotes phosphorylated forms of hIRF7 (left). Relative amounts of p-hIRF7 at various time points were expressed as the intensity of the
band detected by anti-p-hIRF antibody at each time point divided by the intensity of the band detected by anti-IRF7 antibody at 0 h after stimulation
(right). A result is representative of three independent experiments. D Traf6
+/+ or Traf6
2/2 MEF cells were infected with retrovirus vectors encoding
mouse IRF7 (mIRF7) carrying the puromycin resistance gene. Puromycin-resistant pools of MEF cells were treated with 10 mg/ml of poly I:C together
with Lipofectamine 2000 (poly I:C+lipo) for the indicated times. Cell lysates were then prepared, and immunoblotting was performed using
antibodies specific to IRF7 and Tubulin. A dot denotes phosphorylated forms of mIRF7. E Traf6
+/+ or Traf6
2/2 MEF cells were infected with NDV
(MOI=5) for the indicated times. Non-ifna4 gene expression was assessed by real-time PCR. Results shown in (A) and (E) indicate the mean6SD of
triplicate determinations and are representative of two independent experiments. NS, not significant. *=P,0.01. **=P,0.05.
doi:10.1371/journal.pone.0005674.g004
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To understand the molecular mechanism of TRAF6-mediated
IRF activation,we searched for TRAF6-associated proteins involved
in RLH signaling. TRAF3, which is involved in the production of
typeIIFNsinresponsetoRNAvirusinfection,associateswithIPS-1,
TBK1, IKKi, and TRAF family member-associated NF-kB
activator (TANK) [24,25,49], all of which are required for
production of type I IFNs. TRAF6 binds to IPS-1 through the
latter’s two consensus TRAF6-binding motifs (Pro-X-Glu-X-X-
Aromatic/Acidic) [22]. These observations led us to investigate
whether TRAF6, like TRAF3, associates with TBK1, IKKi, and
TANK in addition to associating with IPS-1. Indeed, transient
transfection experiments in 293T cells revealed that TRAF6
associates with IPS-1, TBK1, IKKi, and TANK (Figure 5A).
TRAF6didnotbindIRF-3,whereasbindingofTRAF6toIRF7was
clearly detectable (Figure 5A), as previously reported [11–13]. These
findings are consistent with our observation that RLH-mediated
activation of IRF7, but not that of IRF3, is impaired in the absence
of TRAF6. TRAF6 may mediate interaction of active TBK1/IKKi
with IRF7 but not with IRF3.
To identify functional interactions of TRAF6 with its binding
partners described above, we investigated whether the TRAF6-
associated protein-enhanced transcription of IFNb-luc, which is
under the control of IRF-responsible elements, is affected by
TRAF6 deficiency. IFNb-luc and an expression vector of one of
the TRAF6-associated protein shown in Figure 5A were co-
transfected into either Traf6
+/+ or Traf6
2/2 MEF cells. Consistent
with the results shown in Figure 1, TRAF6 deficiency inhibited the
activation of IFNb promoter caused by overexpression of the N-
terminal CARD domain of RIG-I (RIG-IN), that of MDA5
(MDA5N), IPS-1 and TBK1 (Figure 5B). In contrast, IRF7-
induced IFNb promoter activation was not affected by TRAF6
deficiency (Figure 5B). Since overexpression of IKKi did not result
in significant activation of IFNb promoter in MEF cells, we have
performed similar experiments using HEK293T cells and ISRE-
luc, which is under the control of IRF-responsible element.
Endogenous TRAF6 expression in HEK293T cells was severely
reduced using siRNA (Figure 5C, left), and IKKi-induced
activation of the ISRE-driven promoter was significantly reduced
in TRAF6-silencing cells (Figure 5C, right). Taken together, these
results strongly suggest that TRAF6, like TRAF3, physically and
functionally associates with RIG-I, MDA5, IPS-1, TANK, TBK1,
and IKKi, and acts upstream of IRF7.
TAK1 and MEKK3 are not essential for the RLH-mediated
signaling pathway
During Toll/IL-1R signaling, TRAF6 acts to function as an E3
ubiquitin ligase to conjugate Lys-63-linked polyubiquitin chains to
TRAF6 and to IKKc [8]. Several lines of evidence indicate that
TAK1 is involved in the activation of NF-kB induced by the TLR-
TRAF6 signal [50], and that activation of TAK1 requires Lys-63-
linked polyubiquitination of TRAF6 [8]. Thus, the ligase-deficient
mutant T6Rm cannot activate TAK1 during TLR signaling.
T6Rm also cannot mediate RLH-induced NF-kB activation
(Figure 3C). Since it has been reported that Ubc13, a subunit of
the E2 ubiquitin-conjugating enzyme complex, is required for
TRAF6-mediated activation of IRF7 [12], we addressed whether
TAK1 is also involved in the RLH pathway. We used Tak1
2/2
MEF cells and Tak1
2/2 MEF cells reconstituted with wild-type
TAK1 via a retroviral vector (Tak1
2/2+TAK1 MEF). In the
absence of TAK1, NDV infection induced slightly higher nuclear
NF-kB binding activity than that observed in control cells
expressing TAK1 (Figure 6A). However, production of IL-6 and
type I IFN in the absence of TAK1 was normal in response to SeV
Cm infection (Figure 6B). Another MAP3K, MEKK3, has been
shown to be involved in the TLR-dependent activation of NF-kB
induced by TRAF6 [51]. We therefore assessed whether MEKK3
functions in RLH signaling. In the absence of MEKK3, NDV
infection induced slightly higher levels of nuclear NF-kB binding
activity than that observed in control cells expressing MEKK3
(Figure 6C). However, MEKK3-deficiency barely affected NDV
infection-induced expression of IkBa, an NF-kB target gene,
whereas expression of ifnb and non-ifna4 in Mekk3
2/2 MEF cells
was significantly higher than in control cells expressing MEKK3
(Figure 6D).
Taken together, these results indicate that although both TAK1
and MEKK3 are critically involved in NF-kB activation that
occurs through the TLR/IL-1R-TRAF6 pathway, neither is
essential for RLH-TRAF6-mediated NF-kB activation. Instead,
these proteins may negatively regulate NF-kB activation. MEKK3
may also act as a negative regulator of the RLH-induced
production of IFN.
TRAF6 is involved in the cytosolic DNA sensing system
Recent studies indicate that cytosolic DNA triggers innate
immune responses [31–34], including the production of type I
IFNs. This led us to examine whether TRAF6 is involved in the
signaling pathway triggered by cytosolic dsDNA. B-DNA, which
forms a right-handed helical structure, induces production of
type I IFNs [32]. In the absence of TRAF6, transfection with B-
DNA induced a lower production of IL-6 and type I IFNs than
that observed in control cells expressing TRAF6 (Figure 7A). We
then analyzed the effect of TRAF6 deficiency on B-DNA-
induced activation of NF-kB and IRFs. B-DNA-induced NF-kB
activation was significantly lower in the absence of TRAF6 than
in its presence (Figure 7B, left). Furthermore, transcription of
IFNb-luc or ISRE-luc was barely enhanced in response to B-
DNA in the absence of TRAF6 (Figure 7B, middle and right).
Requirement of TRAF6 in efficient expression of Ifnb was also
observed when MEF cells were transfected with IFN stimulatory
DNA (ISD) instead of B-DNA (Figure 7C). Interestingly, B-
DNA-induced production of IFNa did not require E3 ligase
activity of TRAF6 as in the case with RLH signaling (Figure 7D).
We could not observe that TRAF6 deficiency affected type I IFN
production in response to HSV-1 infection and its replication
(data not shown). This may be due to severe suppression of type I
IFN production by HSV-1 (1–6 pg/ml (below quantitative range
of ELISA) in HSV-1 infection, 600–1000 pg/ml in SeV and
NDV infection).
We next addressed the role of TRAF6 in the activation of IRF3
and IRF7. B-DNA-induced dimerization of IRF3 was normal in
both Traf6
+/+ and Traf6
2/2 MEF cells (Figure 8A). However,
impaired phosphorylation of exogenously expressed hIRF7 was
observed in Traf6
2/2 MEF cells after B-DNA stimulation
(Figure 8B). Moreover, the more slowly migrating form of hIRF7
was barely detectable in Traf6
2/2 MEF cells (Figure 8B),
indicating that TRAF6 is involved in the B-DNA-induced
activation of IRF7. Impaired activation of IRF7 is further
supported by the fact that expression of non-ifna4, which is
regulated by IRF7, is significantly lower in the absence of TRAF6
than in its presence (Figure 8C). These results indicate that
TRAF6 is involved in B-DNA-mediated, as well as RLH-
mediated, activation of NF-kB and IRF7.
Discussion
In this study, we clearly demonstrate that TRAF6 is involved in
cytosolic RNA- and DNA-induced antiviral responses that lead to
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deficiency resulted in a significant reduction in the production of
these cytokines in response to RNA virus infection or transfection
with synthetic dsRNA or B-DNA. Consistent with these results,
NF-kB activation induced by cytosolic RNA or DNA was
impaired; moreover, the activation of IRF7, but not that of
IRF3, was significantly reduced in the absence of TRAF6.
Involvement of TRAF6 in RLH signaling has been controver-
sial. In contrast to what we show here, two groups previously
reported that TRAF6 is not involved in RLH-mediated antiviral
responses by showing that Traf6
2/2 MEF cells produce normal
levels of type I IFNs in response to infection with wild-type SeV
[21,28]. The discrepancy between our results and previous reports
may be due to the use of different viruses. We used the Cm and V-
mutants of SeV; these mutations inhibit antiviral responses in host
cells [37,38]. Previous studies utilized wild-type (WT) SeV. In fact,
as in the previous reports, we found that production of type I IFNs
in response to WT SeV infection was not affected by TRAF6
Figure 5. TRAF6 associates with TANK, TBK1, IKKi, and IRF7. A HEK293T cells were transiently transfected with the plasmid expressing Myc-
tagged TRAF6 together with that encoding FLAG-tagged IPS-1, TBK1, IKKi, IRF7, IRF3, or TANK. Cell lysates were subjected to immunoprecipitation
with anti-FLAG antibody, followed by immunoblotting. B Traf6
+/+ and Traf6
2/2 MEF cells were transfected with IFNb-luc reporter plasmid together
with the plasmid expressing RIG-IN, MDA5N, IPS-1, TBK1, or IRF7. At 48 h after transfection, cell lysates were prepared and analyzed for promoter
activity using the luciferase assay. Values of luciferase activity when overexpressing each activator protein in TRAF6
+/+ MEF cells were set to 100. C
HEK293T cells were transfected with TRAF6-specific siRNA using RNAi MAX (+) or treated with RNAi MAX alone (2) (left). At 24 h after the initial
transfection, the cells were further transfected with ISRE-luc reporter plasmid together with the plasmid expressing IKKi. At 24 h after the second
transfection, cell lysates were prepared and analyzed for promoter activity using the luciferase assay. A value of luciferase activity when
overexpressing IKKi protein without silencing TRAF6 was set to 100 (right). Results shown in (B) and (C) indicate the mean6SD of triplicate
determinations and are representative of two independent experiments. *=P,0.01. **=P,0.05.
doi:10.1371/journal.pone.0005674.g005
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2/2
MEF cells (Figure S3). The precise reasons for the distinct TRAF6
dependency between the antiviral response to WT SeV and the
response to mutant SeVs remain to be elucidated. To confirm the
function of TRAF6 against RNA virus infection, we used other
RNA viruses NDV and EMCV. Replication of NDV and EMCV
was significantly higher in Traf6
2/2 MEF cells than in Traf6
+/+
MEF cells (Figure 2B and 2C). Moreover, in response to NDV
Figure 6. TAK1 and MEKK3 are not essential in RLH-mediated pathways. A Tak1
2/2 MEF cells and those ectopically expressing TAK1
(Tak1
2/2+TAK1) were infected with NDV (MOI=5) for the indicated times. EMSAs were then performed. Expression of exogenous TAK1 is shown
(right). B Tak1
2/2+TAK1 MEF cells and Tak1
2/2 MEF cells were infected with SeV Cm (MOI=10) for 24 h. The amounts of IL-6 (right), IFNa (middle),
and IFNb (left) present in the culture media were measured by ELISA. C Mekk3
2/2 MEF cells and those ectopically expressing MEKK3 (Mekk3
2/2
+MEKK3) were infected with NDV (MOI=5) for the indicated times. EMSAs were then performed. Expression of exogenous MEKK3 is shown (right). D
Mekk3
2/2+MEKK3 MEF cells and Mekk3
2/2 MEF cells were infected with NDV (MOI=5) for the indicated times. Expression of the ifnb (left), non-ifna4
(middle), and IkBa (right) genes was assessed by real-time PCR. Results shown in (B) and (D) indicate the mean6SD of triplicate determinations and
are representative of two independent experiments. ND, not detected. *=P,0.01. **=P,0.05.
doi:10.1371/journal.pone.0005674.g006
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production of type I IFNs was significantly lower in the absence of
TRAF6 (Figure 2B and 4E). EMCV infection-induced activation
of the IFNb promoter was also impaired in Traf6
2/2 MEF cells
(Figure 1B). It has recently been reported that production of type I
IFNs derived from DCs and MEF cells in response to infection
with vesicular stomatitis virus (VSV) is significantly lower in the
absence of TRAF6 [30]. Therefore, TRAF6 has been shown to be
essential for sufficient antiviral responses to infection with four
different RNA viruses, leading to the conclusion that TRAF6 is
involved in RLH signaling.
Although TRAF6 is clearly involved in the RLH signaling
pathway, inhibition of IFN production in response to RNA virus
infection due to TRAF6 deficiency was partial in the present
Figure 7. TRAF6 is involved in cytosolic dsDNA-induced innate immune responses. A Traf6
+/+ or Traf6
2/2 MEF cells were transfected with
10 mg/ml of B-DNA (B-DNA+lipo). At 12 h after transfection, the amounts of IL-6 (left), IFNa (middle), and IFNb (right) present in the culture media
were measured by ELISA. B Traf6
+/+ or Traf6
2/2 MEF cells were transiently transfected with NF-kB-luc (left), IFNb-luc (middle), or ISRE-luc (right)
reporter plasmid. At 48 h after the initial transfection, MEF cells were transfected with 10 mg/ml of B-DNA (B-DNA+lipo) for 6 h. Cell lysates were then
analyzed for promoter activity by the luciferase assay. C Traf6
+/+ or Traf6
2/2 MEF cells were transfected with 5 mg/ml of ISD (ISD+lipo). Ifnb gene
expression was assessed by real-time PCR. D Traf6
+/+ MEF cells, Traf6
2/2 MEF cells, and those exogenously expressing TRAF6 or T6Rm were
transfected with 10 mg/ml of B-DNA (B-DNA+lipo). At 12 h after transfection, the amounts of IFNa present in the culture media were measured by
ELISA. All results shown in Figure 7 indicate the mean6SD of triplicate determinations and are representative of two independent experiments. ND,
not detected. *=P,0.01. **=P,0.05.
doi:10.1371/journal.pone.0005674.g007
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-independent pathways leading to IFN production. Similarly, type
I IFN production has been reported to be partially blocked in
Traf3
2/2 MEF cells [24,25]. Furthermore, TRAF3 and TRAF6
independently bind to their own specific binding sites in IPS-1
[22,25]. Therefore, TRAF3 may regulate the TRAF6-indepen-
dent production of type I IFNs. We also showed that RLH
pathway-dependent NF-kB activation requires TRAF6 (Figure 3B
and 3C), whereas TRAF3 deficiency does not affect the activation
of NF-kB or expression of NF-kB target genes, such as IkBa
[24,25]. Furthermore, TRAF6-induced activation of IRF is likely
to be specific for IRF7, while TRAF3 is thought to activate both
IRF3 and IRF7 [3]. These results strongly suggest that the
TRAF6- and TRAF3-dependent pathways are likely to bifurcate
at IPS-1, but to converge later at IRF7 in order to co-operatively
induce sufficient production of type I IFNs during RLH signaling.
Since phosphorylation of IRF7 is thought to be catalyzed by
TBK1/IKKi [27], TRAF6 may activate TBK1/IKKi in response
to cytosolic RNA and DNA. A previous study has shown that
TRAF6 induces the polyubiquitination of IRF7 when both are
transiently transfected into HEK293T cells [12]. It has been also
reported that Lys-444, -446, and -452 of IRF7 are critical
ubiquitin sites catalyzed by TRAF6, when IRF7 is activated by
latent membrane protein 1 (LMP1), a member of the TNF
receptor superfamily, of Epstein-Barr virus [52]. In contrast, we
show here that E3 ligase activity of TRAF6 is not required for
production type I IFN (Figure 3F and 7D), which strongly suggests
that Lys-63-linked polyubiquitination is not involved in IRF7
activation. Further studies are required in order to elucidate the
details of TRAF6-mediated IRF7 activation.
Previous studies have shown that TAK1 and MEKK3 are
involved in NF-kB activation in TLR family signaling pathways
[50,51,53], and that the E3 ligase activity of TRAF6 is required for
TAK1 activation [8]. Since RLH-induced NF-kB activation
requires the RING domain of TRAF6, the polyubiquitination
reaction may also be involved in NF-kB activation in response to
viral infection. Therefore, we postulated that TAK1 and MEKK3
are candidate MAP3Ks acting downstream of TRAF6 to activate
IKK during RLH signaling. Surprisingly, TAK1 and MEKK3
were not essential for RLH-mediated NF-kB activation and
production of IL-6 and IFNs (Figure 6). Interestingly, NDV
infection-induced production of type I IFNs was slightly higher in
the absence of MEKK3 than in its presence (Figure 6D). During
the preparation of this manuscript, Yoshida et al. reported that
TRAF6 is involved in the RLH antiviral pathway, and that
MEKK1 acts downstream of TRAF6 to induce NF-kB activation
and type I IFN production [30]. However, activation of NF-kBi n
response to NDV infection was normal in Mekk1
2/2 MEF cells
(Figure S4A), whereas production of type I IFNs was slightly
reduced in the absence of MEKK1 (Figure S4B). These results
clearly indicate that the pathway downstream of TRAF6 in RLH
signaling is distinct from that associated with TLR family signaling
Although MEKK1 and MEKK3 are not essential for RLH-
induced activation of NF-kB, they may be involved in fine-tuning
the level of IFN production in response to viral infection. It has
been previously reported that caspase-8 is involved in RLH-
induced NF-kB activation [54]. Therefore, one possible mecha-
nism is that TRAF6 activates caspase-8, which leads to NF-kB
activation. However, further studies are needed to clarify the
Figure 8. TRAF6 is involved in B-DNA-induced IRF7 activation.
A Traf6
+/+ or Traf6
2/2 MEF cells were transfected with 10 mg/ml of B-
DNA (B-DNA+lipo) for the indicated times. Cell lysates were then
prepared, and dimerization of IRF3 was analyzed by native PAGE.
Immunoblot analysis was performed using anti-IRF3 antibody. B Traf6
+/+
or Traf6
2/2 MEF cells were infected with the retroviral vector encoding
hIRF7 and containing the puromycin resistance gene. Puromycin-resistant
pools of MEF cells were transfected with 10 mg/ml of B-DNA (B-DNA+lipo)
for the indicated times. Cell lysates were prepared and immunoblotting
was performedwith antibodies specificfor phospho-hIRF7 (p-hIRF7), IRF7,
TRAF6, and Tubulin. An arrowhead denotes phosphorylated forms of
hIRF-7. C Traf6
+/+ or Traf6
2/2 MEF cells were transfected with 10 mg/ml of
B-DNA (B-DNA+lipo) for the indicated times. Non-ifna4 gene expression
was assessed by real-time PCR. Results shown in (C)i n d i c a t et h e
mean6SD of triplicate determinations and are representative of two
independent experiments. *=P,0.01.
doi:10.1371/journal.pone.0005674.g008
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activation during RLH signaling.
Recent studies have demonstrated that cytosolic DNA is
recognized by cytosolic DNA sensors and that antiviral responses
are induced by signals mediated by TBK1/IKKi, which is distinct
from the signal pathway downstream of TLR9, for which DNA
recognition occurs at endosomes [31–34]. Here we demonstrate
that TRAF6 is involved in antiviral responses induced by B-DNA,
including production of IL-6 and type I IFNs (Figure 7A). In the
cytosolic DNA-induced pathway, TRAF6 regulates activation of
NF-kB and IRF7, but not that of IRF3 (Figure 7B, 7C, 8A and
8B), similar to the role of TRAF6 in RLH-mediated pathways.
However, the molecular mechanisms responsible for transducing
antiviral signals are likely to differ between the RNA and DNA
sensing pathways [35,36]. Absent in melanoma 2 (AIM2) has
recently been identified as a cytoplasmic DNA sensor, which
activates caspase-1 leading to maturation of pro-IL-1b [55–58].
Although AIM2 is thought to be involved in NF-kB activation but
not in IFNb production in response to cytoplasmic dsDNA, the
precise molecular mechanisms of the cytosolic DNA sensing
system remain to be elucidated.
In response to systemic viral infection, pDCs produce type I
IFNs by recognizing viral nucleic acids through TLR7 and TLR9,
while production of type I IFNs in cDCs depends on RLH and
cytosolic DNA sensors [5]. TRAF6 is indispensable not only for
NF-kB activation and the resulting induction of proinflammatory
cytokines [59], but also for production of type I IFNs during TLR7
and TLR9 signaling [60]. In the present report, we demonstrate
that TRAF6 is involved in the cytosolic RNA- and DNA-induced
production of proinflammatory cytokines and type I IFNs. Thus,
TRAF6 makes crucial contributions to antiviral innate immune
responses by sensing not only viral nucleic acids encapsulated in
endosomes but also those present in the cytosol. In addition to its
role in innate immune responses, TRAF6 is essential for
establishing the acquired immune system as a signal transducer
of CD40 [61], RANK [62,63], and TCR [64], indicating that
TRAF6 is a key molecule for the entire immune system.
Therefore, a further understanding of the molecular mechanism
associated with TRAF6-mediated signal transduction is required
in order to enable the development of therapies against various
immune diseases.
Materials and Methods
Mice, cell culture, and viruses
The generation of Traf6
2/2 mice has been described [62].
Primary Traf6
2/2 MEF cells and C57BL/6 MEF cells were
prepared from E14.5 embryos. Mekk1
2/2 [65], Mekk3
2/2 [51],
and Tak1
2/2 [53] MEF cells were prepared as described. MEF
cells, HEK293T cells, and Vero cells were cultured in DMEM
supplemented with 10% FBS. SeV WT (Z strain), Cm, and V-
strains were prepared as previously described [37,66]. NDV was
kindly provided by T. Abe and Y. Matsuura (Osaka University,
Osaka, Japan). EMCV was kindly provided by F. Taguchi
(National Institute of Infectious Disease, Tokyo, Japan). HSV-1
was prepared as previously described [67].
Plasmids
The plasmids p125-luc (IFNb-luc), p55C1B-luc (ISRE-luc),
pEF-FLAG-RIG-IN, and pEF-FLAG-MDA5N were kindly pro-
vided by T. Fujita (Kyoto University, Kyoto, Japan). The plasmid
pcDNA3-FLAG-MAVS (IPS-1) was kindly provided by Z. J. Chen
(University of Texas Southwestern Medical Center, Texas, USA).
The plasmid pGL-3kB-luc (NF-kB-luc) was constructed by
inserting three kB sites and a thymidine kinase (tk) promoter into
the appropriate sites in pGL4.12 (Promega). Mouse cDNA for
IRF3 was amplified from MEF cells using gene-specific PCR
primers and inserted into the XhoI/NotI site of the pME vector
with an N-terminal FLAG tag. The retroviral vectors encoding
TAK1, MEKK3, TRAF6, T6Rm, and IRF7 were constructed by
inserting each cDNA generated by PCR into the appropriate sites
in the pMx-puro vector. The b-galactosidase expression vector
driven by the b-actin promoter (b-actin-b-gal) [68], pEFBOS-
FLAG-TANK [69], pEFBOS-FLAG-IKKi [70], pEFBOS-FLAG-
TBK1 [71], pFLAG-CMV2-mIRF7 [12], and pME-Myc-TRAF6
[68] were prepared as previously described.
Infection of virus and transfection of RNA and DNA
For viral infection, cells were incubated with viruses at the
indicated MOI for 1 h in MEM without FBS (SeV, NDV) or
Medium 199 with 1% FBS (HSV-1) before replacement with
DMEM containing 10% FBS. Excess virus was washed away 1 hr
after infection. MEF cells were infected with SeV, NDV, or HSV-
1 for 24 h or transfected with 10 mg/ml of poly I:C (InvivoGen,
San Diego, CA), 1 mg/ml of in vitro-transcribed dsRNA (600 bp)
[39], 10 mg/ml of B-DNA (poly(dA-dT)-poly(dT-dA), Sigma-
Aldrich, St. Louis, MO), or ISD [33] for 12 h using Lipofectamine
2000 (Invitrogen, Carlsbad, CA).
ELISA and Real-time PCR
Culture supernatants were collected and analyzed by ELISA to
measure production of IL-6 (R&D systems, Minneapolis, MN),
IFNa, and IFNb (PBL Biomedical Laboratories, Piscataway, NJ).
Total RNA was isolated from cells using Trizol Reagent
(Invitrogen) and cDNA synthesis was performed using PrimeScript
II (Takara Bio, Shiga, Japan). Real-time RT-PCR analysis was
performed using the 7300 system (Applied Biosystems, Foster City,
CA) and SYBR Green (Roche, Mannheim, Germany). The level
of b-actin expression in each sample was used to standardize the
data. The primers used for b-actin, ifnb, IkBa, and non-ifna4 have
been previously described [41].
Luciferase assay
Using Lipofectamine 2000, we transiently transfected MEF cells
with reporter plasmids and Renilla luciferase plasmid as an internal
control in the presence or absence of expression plasmid for
various activator of RLH pathways. At 48 h after the initial
transfection, MEF cells were infected with EMCV (MOI=1) for
20 h, or transfected with either poly I:C (10 mg/ml) or B-DNA
(10 mg/ml) for 6 h using Lipofectamine 2000. Subsequently cells
were analyzed in dual luciferase reporter assays (Promega,
Madison, WI). HEK293T cells were transfected with the
TRAF6-specific siRNA (Invitrogen) using RNAi MAX (Invitro-
gen). At 24 h after siRNA treatment, cells were transiently
transfected with ISRE-luc, various expression plasmids, and b-
actin-b-gal as an internal control using the calcium phosphate
method. At 24 h after transfection, the cells were lysed and
subjected to the PicaGene luciferase assay (Toyo Ink, Tokyo,
Japan). b-galactosidase activity was used to standardize the
transfection efficiency. The TRAF6-specific siRNA (59-CCAC-
GAAGAGAUAAUGGAUGCCAAA-39) was used to suppress
endogenous TRAF6 expression [72].
Plaque assay
Culture supernatants were collected from MEF cells infected
with NDV for the indicated times. For EMCV and HSV-1,
infected cells were freeze-thawed, and the supernatants were used.
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incubated with serial dilutions of the supernatants for 1 h, and
then overlaid with 1% low-melting agarose for NDV or Medium
199 with human g-globulin for HSV-1. For EMCV, L929 cells
were used instead of Vero cells and overlaid with 1%
carboxymethylcellulose. After incubation for 48 h, the cells were
fixed with 4% paraformaldehyde for NDV or methanol for HSV-1
and EMCV. Cells were then stained with 0.05% amido black for
NDV or 0.05% crystal violet for HSV-1 and EMCV. Numbers of
plaques were counted in order to calculate the viral titer.
Electrophoretic mobility shift assay (EMSA)
MEF cells were infected with SeV Cm (MOI=10) or NDV
(MOI=5) and harvested at the indicate times. Cells were
suspended in hypotonic buffer [10 mM HEPES (pH 7.9),
1.5 mM MgCl2, 10 mM KCl, 0.5 mM dithiothreitol (DTT), and
0.4 mM phenylmethylsulfonyl fluoride (PMSF)]. The suspension
was maintained on ice for 20 min, and the cells were then
disrupted by pipetting. The supernatant was removed, and the
pelleted nuclei were incubated with extraction buffer [20 mM
HEPES (pH 7.9), 1.5 mM MgCl2, 420 mM NaCl, 0.2 mM
EDTA, 0.5 mM DTT, 0.4 mM PMSF and 25% glycerol]. The
suspension was incubated on ice for 20 min, and the nuclear
extract was obtained from the supernatant. Equal amounts of
extracts were incubated for 25 min at room temperature with
32P-
labeled oligonucleotide containing the NF-kB binding site of the
Igk light chain gene (59-AGCTTCAGAGGGGACTTTCCGA-
GAGG-39,5 9-TCGACCTCTCGGAAAGTCCCCTCTGA-39),
and 0.05 mg/ml of poly dI:dC. Binding reactions were carried
out in the following buffer: 15 mM Tris-HCl (pH 7.5), 75 mM
NaCl, 1.5 mM EDTA, 1.5 mM DTT, 7.5% glycerol, 0.3%
Nonidet P-40 (NP-40), and 1 mg/ml bovine serum albumin (BSA).
Electrophoresis was performed in a 4% acrylamide gel at 150 V
for 90 min. The gel was then dried and exposed to film (Kodak,
Rochester, NY). The supershift assay was performed by addition
of anti-FLAG antibody (Sigma-Aldrich) or anti-p65 antibody
(Santa Cruz Biotechnology, Santa Cruz, CA) to the binding
reaction. The competition assay was performed by addition of
unlabeled probe oligonucleotide or an oligonucleotide containing
the AP-1 binding site (59-AGCTTCGCTTGATGACT-
CAGCCGGAA-39,5 9-GATCCTTCCGGCTGAGTCAT-
CAAGCG-39).
Native PAGE
MEF cells were infected with either SeV Cm (MOI=10) or
NDV (MOI=5), or transfected with 10 mg/ml of poly I:C or B-
DNA for the indicated times. Cell lysates were prepared in TNE
buffer [50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA,
1% NP-40, 1 m Na3VO4, 1 mM PMSF]. A 7.5% native
acrylamide gel was pre-run at 40 mA for 30 min, then loaded
with samples and run at 25 mA for 50 min. The upper chamber
buffer was Tris-HCl (pH 8.4), 192 mM glycine, and 0.2% sodium
deoxycholate; the lower chamber buffer was Tris-HCl (pH 8.4)
and 192 mM glycine. The proteins on the PAGE gel were blotted
onto Immobilon-P PVDF membrane (Millipore, Bedford, MA) in
transfer buffer [24 mM Tris-HCl (pH 8.4), 192 mM glycine, 20%
methanol] at 100 mA for 60 min. The membrane was blocked for
1 h with TBST [20 mM Tris-HCl (pH 7.4), 75 mM NaCl, 0.05%
Tween-20] containing 5% nonfat dry milk, and then incubated for
1 h with anti-IRF3 antibody (Zymed, Carlsbad, CA) in blocking
solution. Next, the membrane was incubated with horseradish
peroxidase (HRP)-conjugated donkey anti-rabbit IgG (GE
Healthcare, Buckinghamshire, UK) in blocking solution for 1 h.
After three washes, the proteins were visualized using the ECL
system (GE Healthcare) and the membrane was exposed to
Hyperfilm ECL (GE Healthcare).
Immunoprecipitation assay
HEK293T cells were transfected with pME-Myc-TRAF6
together with various FLAG-tagged expression plasmids using
the calcium phosphate method. At 48 h after transfection, cell
lysates were prepared in TNE buffer and incubated with anti-
FLAG antibody (Sigma-Aldrich) at 4uC for 1 h. Protein G
sepharose (GE Healthcare) was then added to the cell lysates,
and the mixture was incubated for 1 h. After three washes, the
immunoprecipitates were boiled in SDS sample buffer for 10 min
and analyzed by immunoblotting.
Immunoblotting
The samples were separated in a 7.5% gel and then transferred
to an Immobilon-P PVDF membrane in transfer buffer. The
membrane was blocked in TBST containing 5% nonfat dry milk
for 1 h, and then incubated in blocking solution or TBST
containing 5% BSA for 1 h with one of the following antibodies:
anti-FLAG (Sigma-Aldrich); anti-Myc, anti-TRAF6, anti-hIRF7,
anti-TAK1 (Santa Cruz Biotechnology); anti-p-JNK (Cell Signal-
ing, Danvers, MA); anti-tubulin (Calbiochem, San Diego, CA);
anti-mIRF7 (Zymed); anti-SeV C (prepared as described) [66];
anti-p-hIRF7 (kindly provided by John Hiscott (McGill University,
Montre ´al, Canada); or anti-MEKK3 (prepared as described) [51].
The membrane was then incubated in blocking solution for 1 h
with HRP-conjugated donkey anti-rabbit IgG or sheep anti-mouse
IgG (GE Healthcare). After three washes, the proteins were
visualized by the ECL system (GE Healthcare) and the membrane
was exposed to Hyperfilm ECL (GE Healthcare). For quantifica-
tion of bands visualized in immunoblotting using anti-p-hIRF7
and anti-hIRF7 antibodies, images of chemiluminescent signals
were captured by LAS-4000 (Fuji film, Tokyo, Japan) and
quantified using Photoshop software (Adobe Systems, San Jose,
CA).
Retrovirus-mediated gene transfer
The packaging cell line, Plate-E cells, were transfected with one
of the following retroviral vectors (pMx-puro, pMx-hIRF7-puro,
pMX-mIRF7-puro, pMx-TAK1-puro, pMx-MEKK3-puro, pMx-
TRAF6-puro, pMx-T6Rm-puro) [73]. At 48 h after transfection,
the culture medium was collected and used to prepare virus stocks.
MEF cells were incubated for 4 h with virus stock containing
10 mg/ml of polybrene. Infected MEF cells were then cultured for
1 day, and then cultured for an additional 2 days with 2 mg/ml of
puromycin to remove uninfected cells.
Statistical analyses
Statistical significance was determined using Student’s t-test. A
P value less than 0.05 was considered statistically significant.
Supporting Information
Figure S1 TRAF6 contributes to reduced expression of C
protein of Sendai virus. Traf6+/+ or Traf62/2 MEF cells were
infected with SeV Cm (MOI=10) for the indicated times. Cell
lysates were then prepared and analyzed for viral C protein
expression by immunoblotting using anti-C protein serum.
Found at: doi:10.1371/journal.pone.0005674.s001 (0.24 MB TIF)
Figure S2 Activation of IRF3 in response to SeV Cm infection
was minimally affected in the absence of TRAF6. Traf6+/+ or
Traf62/2 MEF cells were infected with SeV Cm (MOI=10) for
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dimerization of IRF3 was analyzed by native PAGE. Immunoblot
analysis was performed using anti-IRF3 antibody.
Found at: doi:10.1371/journal.pone.0005674.s002 (0.31 MB TIF)
Figure S3 Comparison of the production of IL-6 and type I
IFNs in response to infection with wild-type SeV or SeV Cm.
Traf6+/+ or Traf62/2 MEF cells were infected with SeV WT or
Cm (MOI=10) for 24 h. The amounts of IL-6 (left), IFNa
(middle), and IFNb (right) in the culture media were measured by
ELISA. Results indicate the mean6SD of triplicate determina-
tions and are representative of two independent experiments. ND,
not detected. NS, not significant. *=P,0.05. **=P,0.05.
Found at: doi:10.1371/journal.pone.0005674.s003 (0.20 MB TIF)
Figure S4 MEKK1 is not essential in RLH-mediated pathways.
(A) Mekk1+/+ and Mekk12/2 MEF cells were infected with
NDV (MOI=5) for the indicated times. EMSAs were then
performed. Lack of Mekk1 expression in Mekk12/2 MEF cells
was confirmed. (B) Mekk1+/+ and Mekk12/2 MEF cells were
infected with NDV (MOI=5) for the indicated times. Expression
of the ifnb (left), non-ifna4 (middle), and IkBa (right) genes was
assessed by real-time PCR. The results indicate the mean6SD of
triplicate determinations and are representative of two indepen-
dent experiments. NS, not significant. **=P,0.05.
Found at: doi:10.1371/journal.pone.0005674.s004 (0.56 MB TIF)
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